These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 36982560)

  • 21. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Herbs for benign prostatic hyperplasia.
    Dvorkin L; Song KY
    Ann Pharmacother; 2002 Sep; 36(9):1443-52. PubMed ID: 12196065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic variants in 5p13.2 and 7q21.1 are associated with treatment for benign prostatic hyperplasia with the α-adrenergic receptor antagonist.
    Qian X; Xu D; Liu H; Lin X; Yu Y; Kang J; Sheng X; Xu J; Zheng S; Xu D; Qi J
    Aging Male; 2017 Dec; 20(4):250-256. PubMed ID: 28787260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of HT080 for lower urinary tract symptoms associated with benign prostatic hyperplasia: A study protocol for a randomized, double-blind, placebo-controlled trial.
    Song J; Lee SH; Kim H
    Medicine (Baltimore); 2019 Nov; 98(45):e17848. PubMed ID: 31702643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Proliferative Effects of HBX-5 on Progression of Benign Prostatic Hyperplasia.
    Jin BR; Kim HJ; Park SK; Kim MS; Lee KH; Yoon IJ; An HJ
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30322186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Saussurea costus on apoptosis imbalance and inflammation in benign prostatic hyperplasia.
    Choi DH; Kim JY; An JH; Sung SH; Kong HS
    J Ethnopharmacol; 2021 Oct; 279():114349. PubMed ID: 34171398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia.
    Shore N
    Expert Opin Investig Drugs; 2010 Feb; 19(2):305-10. PubMed ID: 20050813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial.
    Zerafatjou N; Amirzargar M; Biglarkhani M; Shobeirian F; Zoghi G
    BMC Urol; 2021 Oct; 21(1):147. PubMed ID: 34666728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dietary supplements and medicinal plants in urolithiasis: diet, prevention, and cure.
    Oswal M; Varghese R; Zagade T; Dhatrak C; Sharma R; Kumar D
    J Pharm Pharmacol; 2023 Jun; 75(6):719-745. PubMed ID: 37130140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cernilton for benign prostatic hyperplasia.
    Wilt T; Mac Donald R; Ishani A; Rutks I; Stark G
    Cochrane Database Syst Rev; 2000; (2):CD001042. PubMed ID: 10796739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ethanol Extract of
    Park E; Lee MY; Seo CS; Jang JH; Kim YU; Shin HK
    Nutrients; 2018 Apr; 10(4):. PubMed ID: 29690562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory Effect of Artemisinin on Testosterone Propionate Induced Benign Prostatic Hyperplasia.
    Solanki A; Patel S; Solanki N; Shah U
    Curr Drug Discov Technol; 2021; 18(4):518-524. PubMed ID: 32532194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors.
    Zitoun OA; Farhat AM; Mohamed MA; Hamad MR; Aramini B; Haider KH
    Eur J Pharmacol; 2020 Sep; 883():173301. PubMed ID: 32592768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostatic hydroablation (Aquablation): A new effective ultrasound guided robotic waterjet ablative surgery for treatment of benign prostatic hyperplasia.
    Lim Ng K; Barber N
    Arch Esp Urol; 2019 Oct; 72(8):786-793. PubMed ID: 31579037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The treatment effects of flaxseed-derived secoisolariciresinol diglycoside and its metabolite enterolactone on benign prostatic hyperplasia involve the G protein-coupled estrogen receptor 1.
    Ren GY; Chen CY; Chen WG; Huang Y; Qin LQ; Chen LH
    Appl Physiol Nutr Metab; 2016 Dec; 41(12):1303-1310. PubMed ID: 27849354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serenoa repens for benign prostatic hyperplasia.
    Wilt T; Ishani A; Mac Donald R
    Cochrane Database Syst Rev; 2002; (3):CD001423. PubMed ID: 12137626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benign prostate hyperplasia and nutrition.
    Das K; Buchholz N
    Clin Nutr ESPEN; 2019 Oct; 33():5-11. PubMed ID: 31451276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.